PF
PFE.US Pfizer Inc
- Market cap
- USD 165B
- P/E
- 41.3x
- P/B
- 1.85x
- ROE
- 8.5%
- Dividend yield
- 5.93%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PFE.US undervalued?
Graham numberPFE.US trades 84.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pfizer Inc fundamental analysis
No fundamental analysis for Pfizer Inc yet.
Pfizer Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, …
Full company profilePfizer Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pfizer Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 52.8B | 52.5B | 40.8B | 40.9B | 41.7B | 81.3B | 101B | 59.6B | 63.6B | 62.6B | 61.4B |
| Gross Profit | 40.5B | 41.3B | 31.8B | 32.9B | 33.2B | 50.5B | 66.8B | 34.6B | 45.8B | 46.5B | 45.9B |
| Operating Income | 13.7B | 14.1B | 6.73B | 7.31B | 8.83B | 20.2B | 38.1B | 4.42B | 14.9B | 17.4B | 15.3B |
| EBITDA | 15.3B | 19.8B | 11.1B | 18.6B | 13.3B | 30.8B | 41.0B | 9.56B | 18.1B | 16.8B | 16.9B |
| Net Income | 7.22B | 21.3B | 11.2B | 16.0B | 9.16B | 22.0B | 31.4B | 2.12B | 8.03B | 7.77B | 7.57B |
| EPS | 5.86 | 18 | 1.87 | 2.82 | 1.63 | 3.85 | 5.47 | 0.37 | 1.41 | 1.37 | 1.32 |
| Balance Sheet | |||||||||||
| Total Assets | 172B | 172B | 159B | 167B | 154B | 181B | 197B | 227B | 213B | 208B | 205B |
| Total Liabilities | 112B | 100B | 95.7B | 104B | 90.8B | 104B | 101B | 137B | 125B | 121B | 115B |
| Shareholders' Equity | 59.8B | 71.7B | 63.8B | 63.4B | 63.5B | 77.5B | 95.9B | 89.3B | 88.2B | 86.5B | 89.0B |
| Cash & Short-term Investments | 17.9B | 20.0B | 18.8B | 9.83B | 12.2B | 31.1B | 22.7B | 12.7B | 20.5B | 13.6B | 14.3B |
| Total Debt | 42.1B | 43.5B | 41.7B | 52.1B | 39.8B | 38.4B | 35.8B | 75.0B | 67.0B | 67.4B | 62.7B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 15.9B | 16.5B | 15.8B | 12.6B | 14.4B | 32.6B | 29.3B | 8.70B | 12.7B | 11.7B | 11.8B |
| Capital Expenditure | 2.00B | 2.22B | 2.20B | 2.59B | 2.79B | 2.71B | 3.24B | 3.91B | 2.91B | 2.63B | 2.06B |
| Free Cash Flow | 13.9B | 14.3B | 13.6B | 9.99B | 11.6B | 29.9B | 26.0B | 4.79B | 9.84B | 9.08B | 9.71B |
| Ratios | |||||||||||
| ROE | 12.1% | 29.7% | 17.5% | 25.3% | 14.4% | 28.4% | 32.7% | 2.4% | 9.1% | 9.0% | 8.5% |
| ROA | 4.2% | 12.4% | 7.0% | 9.6% | 5.9% | 12.1% | 15.9% | 0.9% | 3.8% | 3.7% | 3.7% |
| Net Profit Margin | 13.7% | 40.6% | 27.3% | 39.2% | 22.0% | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% | 12.3% |
| Debt to Equity | 0.70x | 0.61x | 0.65x | 0.82x | 0.63x | 0.50x | 0.37x | 0.84x | 0.76x | 0.78x | 0.70x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pfizer Inc dividends
- Dividend yield
- 5.93%
- Forward dividend
- 1.72 USD
- Payout ratio
- 125.7%
- Ex-dividend date
- Nov 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 9.77B | 1.72 | 125.7% |
| 2024 | USD 9.51B | 1.67 | 118.4% |
| 2023 | USD 9.25B | 1.62 | 436.4% |
| 2022 | USD 8.98B | 1.57 | 28.6% |
| 2021 | USD 8.73B | 1.53 | 39.7% |
| 2020 | USD 8.44B | 1.50 | 92.1% |
| 2019 | USD 8.04B | 1.42 | 50.2% |
| 2018 | USD 7.98B | 1.33 | 71.5% |
| 2017 | USD 7.66B | 6.32 | 35.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1054:1000 on Nov 17, 2020.
Who owns Pfizer Inc
- Insiders 0.26%
- Institutions 69.27%
- Public & others 30.48%
- Shares outstanding 5.70B
- Free float 5.69B
Top funds holding PFE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 181M | 3.17% | -0.12% | Sep 2026 |
| Vanguard 500 Index Investor | 150M | 2.63% | -1.15% | Sep 2026 |
| iShares Core S&P 500 ETF | 76.0M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 74.1M | 1.30% | +0.12% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 69.5M | 1.22% | -0.25% | Oct 2026 |
| Vanguard MStar Value Index Investor | 54.3M | 0.95% | -0.35% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 41.7M | 0.73% | +0.88% | Oct 2026 |
| Vanguard Institutional Index I | 30.1M | 0.53% | -1.05% | Sep 2026 |
| Vanguard High Dividend Yield ETF | 23.2M | 0.41% | +0.27% | Sep 2026 |
| iShares Select Dividend ETF | 19.1M | 0.33% | +0.19% | Oct 2026 |
| First Trust Morningstar Div Leaders ETF | 18.0M | 0.32% | +0.06% | Oct 2026 |
| MFS Value A | 17.5M | 0.31% | +6.23% | Sep 2026 |
| Vanguard Health Care ETF | 17.4M | 0.31% | +0.12% | Sep 2026 |
| VanEck Morningstar DevMrkts Div Lead ETF | 17.3M | 0.30% | +0.03% | Oct 2026 |
| State Street® SPDR® Port S&P 500® ETF | 15.9M | 0.28% | -0.07% | Oct 2026 |
| American Funds New Perspective A | 14.5M | 0.25% | 0.00% | Sep 2026 |
| Pacer US Cash Cows 100 ETF | 13.9M | 0.24% | +0.13% | Oct 2026 |
| iShares Core S&P 500 ETF USD Acc | 13.7M | 0.24% | 0.00% | Oct 2026 |
| Schwab® S&P 500 Index | 12.8M | 0.22% | +0.00% | Sep 2026 |
| iShares Russell 1000 Value ETF | 12.5M | 0.22% | +0.02% | Oct 2026 |
Top institutions holding PFE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 530M | 9.29% | +6.30% | Jun 2026 |
| Vanguard Capital Management, LLC | 372M | 6.53% | +0.74% | Jun 2026 |
| State Street Corp | 307M | 5.39% | +1.82% | Jun 2026 |
| Geode Capital Management, LLC | 135M | 2.37% | +1.28% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 119M | 2.09% | +2.14% | Jun 2026 |
| Fisher Asset Management, LLC | 109M | 1.91% | +3.91% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 96.3M | 1.69% | +3.95% | Jun 2026 |
| NORGES BANK | 61.5M | 1.08% | -16.36% | Jun 2026 |
| Northern Trust Corp | 59.1M | 1.04% | -4.74% | Jun 2026 |
| Bank of New York Mellon Corp | 57.9M | 1.02% | +7.42% | Jun 2026 |
| Massachusetts Financial Services Company | 56.6M | 0.99% | -0.63% | Jun 2026 |
| State Farm Mutual Automobile Ins Co | 54.5M | 0.96% | 0.00% | Sep 2026 |
| The Goldman Sachs Group Inc | 53.0M | 0.93% | +12.50% | Jun 2026 |
| Charles Schwab Investment Management Inc | 52.5M | 0.92% | +1.27% | Jun 2026 |
| Bank of America Corp | 43.6M | 0.76% | -6.35% | Jun 2026 |
| Legal & General Group PLC | 43.2M | 0.76% | -0.63% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 38.5M | 0.68% | +1.22% | Sep 2026 |
| UBS Asset Mgmt Americas Inc | 36.2M | 0.63% | +4.73% | Jun 2026 |
| Amundi | 33.5M | 0.59% | -17.86% | Jun 2026 |
| Royal Bank of Canada | 32.8M | 0.58% | -3.93% | Jun 2026 |
Pfizer Inc company profile
- Company name
- Pfizer Inc
- Ticker
- PFE.US
- Exchange
- USA Stocks
- Listed since
- Jun 22, 1942
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 75,000
- Fiscal year end
- December
- Address
- 66 Hudson Boulevard East, New York, NY, United States, 10001-2192
- Phone
- 212 733 2323
- Website
- pfizer.com
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer Inc management
10- Dr. Albert Bourla D.V.M., Ph.D.Chairman of the Board & CEO · born 1962
- Dr. Chris Boshoff FMedSci, M.D., Ph.D.Chief Scientific Officer and President of Research & Development · born 1964
- Mr. Douglas M. LanklerExecutive VP & Chief Legal Officer · born 1966
- Mr. Aamir MalikExecutive VP & Chief U.S. Commercial Officer · born 1976
- Ms. Cecile GueganExecutive VP & CFO · born 1971
- Ms. Jennifer B. DamicoSenior VP, Controller & Principal Accounting Officer · born 1969
- Mr. Dennis P. HancockExecutive VP & Chief Information Officer
- Ms. Francesca M. DeMartinoChief Investor Relations Officer
- Ms. Payal Sahni BecherChief People Experience Officer & Executive VP · born 1975
- Dr. Michael S. Vincent M.D., Ph.D.Senior VP and Chief Scientific Officer of Inflammation & Immunology